These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22503954)

  • 21. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
    Ahn S; Lee IH; Lee E; Kim H; Kim YC; Jon S
    J Control Release; 2013 Sep; 170(2):226-32. PubMed ID: 23747732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What have we learned about the treatment of type 2 diabetes? The evolving paradigms.
    Freeman JS; Horton ES
    Am J Ther; 2012 Nov; 19(6):449-64. PubMed ID: 23154228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH
    Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
    Nauck MA; Holst JJ; Willms B; Schmiegel W
    Exp Clin Endocrinol Diabetes; 1997; 105(4):187-95. PubMed ID: 9285204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exenatide once weekly in type 2 diabetes mellitus.
    Bischoff LA; Jabbour SA; Miller JL
    Expert Opin Pharmacother; 2011 Jun; 12(8):1297-1303. PubMed ID: 21548720
    [No Abstract]   [Full Text] [Related]  

  • 29. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery.
    Chen MC; Sonaje K; Chen KJ; Sung HW
    Biomaterials; 2011 Dec; 32(36):9826-38. PubMed ID: 21925726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].
    Sjöholm A; Agardh CD; Brismar K; Efendic S; Eliasson B; Eriksson JW; Frid A; Groop L; Holmgren J; Ridderstråle M; Smith U
    Lakartidningen; 2008 Apr 23-May 6; 105(17-18):1310, 1312. PubMed ID: 18561535
    [No Abstract]   [Full Text] [Related]  

  • 35. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
    Martin CL
    Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone copycats.
    Gebel E
    Diabetes Forecast; 2012 Jun; 65(6):36, 38-9. PubMed ID: 22737769
    [No Abstract]   [Full Text] [Related]  

  • 37. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
    Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
    Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).
    Park EJ; Lim SM; Lee KC; Na DH
    Expert Opin Ther Pat; 2016 Jul; 26(7):833-42. PubMed ID: 27196800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach.
    Soudry-Kochavi L; Naraykin N; Nassar T; Benita S
    J Control Release; 2015 Nov; 217():202-10. PubMed ID: 26381898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.